PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
نویسندگان
چکیده
منابع مشابه
Budget Impact Analysis of Introducing Biosimilar Infliximab for the Treatment of Auto Immune Disorders In Five European Countries.
estimate was based on prevalence data for URDs for which patented drugs are currently available and for which drugs are in clinical development and hence may be expected to be launched in the foreseeable future. A power function was used to estimate the relation between (decreasing) prevalence and (increasing) cost per patient. For drugs in development, we applied phase duration data and attrit...
متن کاملFirst-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.
AIM To carry out a cost minimisation analysis including a comparison of the costs arising from first-line treatment by bevacizumab plus docetaxel (BD) versus bevacizumab plus paclitaxel (BP) of patients with metastatic breast cancer (mBC). PATIENT AND METHODS All consecutive patients with human epidermal growth receptor 2-negative mBC and treated at Besançon University hospital between 2006 a...
متن کاملThe Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
INTRODUCTION Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a considerable impact on patients' quality of life and healthcare budgets. Biosimilar infliximab (Remsima(®)) has been authorized by the European Medicines Agency for the management of inflammatory autoimmune diseases based on...
متن کاملTacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
BACKGROUND The economic impact of therapies has increasingly become part of the clinical decision-making process. Costs associated with kidney transplantation are substantial and economic evaluations are useful in identifying immunosuppressive regimens that yield optimal clinical and economic benefits. METHODS Utilisation of health care resources during the first 6-months after renal transpla...
متن کاملCost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients
Current practice guidelines for the treatment of COPD recommend the use of combined inhaled corticosteroids and long-acting bronchodilators in severe and very severe patients (GOLD stages III and IV). The aim of this study was to evaluate, through a simulation model, the economic consequences of this recommendation in Italy. We developed a cost-effectiveness analysis (CEA) on five alternative t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2019
ISSN: 1098-3015
DOI: 10.1016/j.jval.2019.09.310